Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study
43
Zitationen
25
Autoren
2016
Jahr
Abstract
BACKGROUND: Extent of resection (EOR) correlates with glioblastoma outcomes. Resectability and EOR depend on anatomical, clinical, and surgeon factors. Resectability likely influences outcome in and of itself, but an accurate measurement of resectability remains elusive. An understanding of resectability and the factors that influence it may provide a means to control a confounder in clinical trials and provide reference for decision making. OBJECTIVE: To provide proof of concept of the use of the collective wisdom of experienced brain tumor surgeons in assessing glioblastoma resectability. METHODS: We surveyed 13 academic tumor neurosurgeons nationwide to assess the resectability of newly diagnosed glioblastoma. Participants reviewed 20 cases, including digital imaging and communications in medicine-formatted pre- and postoperative magnetic resonance images and clinical vignettes. The selected cases involved a variety of anatomical locations and a range of EOR. Participants were asked about surgical goal, eg, gross total resection, subtotal resection (STR), or biopsy, and rationale for their decision. We calculated a "resectability index" for each lesion by pooling responses from all 13 surgeons. RESULTS: Neurosurgeons' individual surgical goals varied significantly ( P = .015), but the resectability index calculated from the surgeons' pooled responses was strongly correlated with the percentage of contrast-enhancing residual tumor ( R = 0.817, P < .001). The collective STR goal predicted intraoperative decision of intentional STR documented on operative notes ( P < .01) and nonresectable residual ( P < .01), but not resectable residual. CONCLUSION: In this pilot study, we demonstrate the feasibility of measuring the resectability of glioblastoma through crowdsourcing. This tool could be used to quantify resectability, a potential confounder in neuro-oncology clinical trials.
Ähnliche Arbeiten
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.481 Zit.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.861 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.920 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.095 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.533 Zit.
Autoren
- Adam M. Sonabend
- Brad E. Zacharia
- Michael Cloney
- Aarón Sonabend
- Christopher R. Showers
- Victoria Ebiana
- Matthew Nazarian
- Kristin R. Swanson
- Anne Baldock
- Henry Brem
- Jeffrey N. Bruce
- William E. Butler
- Daniel P. Cahill
- Bob S. Carter
- Daniel A. Orringer
- David W. Roberts
- Oren Sagher
- Nader Sanai
- Theodore H. Schwartz
- Daniel L. Silbergeld
- Michael B. Sisti
- Reid C. Thompson
- Allen Waziri
- Zoher Ghogawala
- Guy M. McKhann
Institutionen
- Harvard University(US)
- Columbia University Irving Medical Center(US)
- Neurological Surgery(US)
- Penn State Milton S. Hershey Medical Center(US)
- WinnMed(US)
- Mayo Clinic in Arizona(US)
- University of California San Diego(US)
- Johns Hopkins University(US)
- Johns Hopkins Medicine(US)
- Massachusetts General Hospital(US)
- University of Michigan(US)
- Dartmouth Psychiatric Research Center(US)
- Barrow Neurological Institute(US)
- NewYork–Presbyterian Hospital(US)
- Cornell University(US)
- University of Washington(US)
- Vanderbilt University Medical Center(US)
- Inova Health System(US)
- Lahey Hospital and Medical Center(US)
- Lahey Medical Center(US)